Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, August 25, 2021 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its `buy' rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK 55 per share. Both of these reports were published before the August 23, 2021 announcement that the Danish Ministry of Health will fund the ABNCoV2 COVID-19 vaccine program with up to DKK 800 million.
Both research reports are available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website. The next updates from Pareto Securities and Analysguiden are expected following major news.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se